By Benjamin Horney (September 8, 2016, 5:32 PM EDT) -- Bayer AG is mulling the sale of its dermatology unit, which could be worth as much as €1 billion ($1.1 billion), Bloomberg reported on Thursday. According to the report, the German chemical and drugmaker has tapped JPMorgan Chase & Co. to assist as it explores a sale of the business. The unit-in-question makes products including eczema treatment Desonate and rosacea treatment Finacea, and potentially interested suitors could include skincare products makers such as Nestle SA's Galderma, Allergan PLC and Almirall SA, as well as private equity firms, the report said. The report comes as Bayer is in the midst of trying to takeover seeds and pesticides mammoth Monsanto....